FDA
-
-
-
-
-
-
-
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
-
-
-
-
-
-
-
AxoGen, Inc. (AXGN) PT Raised to $40 at Leerink Partners
-
-
-
-
-
-
-
AxoGen, Inc. (AXGN) PT Raised to $27 at Canaccord Genuity
-
-
-
-
-
-
-
Axogen, Inc. Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
-
-
-
-
-
-
-
Axogen, Inc Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

